AZD4831

Phase 2Small molecule

AstraZeneca

AZD4831 is one of 104 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

FibrosisActive, not recruiting

Heart FailureActive, not recruiting

Cardiovascular DiseasePhase 1

Active, not recruiting

FibrosisPhase 2

Active, not recruiting

Heart FailurePhase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

AZD4831

AstraZeneca

Phase 2

2 2

Brethine

Sanofi

Preclinical

1 3

Amidate

Pfizer

Preclinical

1 4

Monoferric

PPharmacosmos A/S

Preclinical

5 5

Zemplar

Xifaxan

2 7

Coumadin

AAbbott

Preclinical

1 8

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Kuvan

BioMarin Pharmaceutical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ESS3 trials

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT02712372·104 enrolled

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04232345·32 enrolled

A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05457270·30 enrolled

Heart Failure2 trials

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT03756285·41 enrolled

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

Completed· AstraZeneca logo

AstraZeneca·Phase 2/3·NCT04986202·711 enrolled

Cardiovascular Disease1 trial

A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03136991·38 enrolled

Renal Impairment1 trial

A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04949438·20 enrolled

Tics1 trial

A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05236543·21 enrolled

2 more indications

Fibrosis1 trial

A Study in Participants With Non-cirrhotic NASH With Fibrosis

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT05638737·112 enrolled

Midazolam1 trial

Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05052710·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for AZD4831. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD4831 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD4831. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD4831

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ESS3 trials

Heart Failure2 trials

Cardiovascular Disease1 trial

Renal Impairment1 trial

Tics1 trial

Fibrosis1 trial

Midazolam1 trial

References

Drug Info

Quick Facts

Related News